Glaukos

GKOS

Market cap $9.21B

Alex R. Thurman generated ~$1.6 million in gross proceeds by selling 10,000 shares at $155 per share on July 9. The disposition represented 19% of the insider's total equity holdings, including shares acquired through a concurrent option exercise.

Abbott Laboratories offers a highly diversified healthcare portfolio with strong profitability across diagnostics and medical devices. Glaukos provides high-growth potential through its specialized focus on disruptive ophthalmic technologies for glaucoma and corneal care.

GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.

This medical stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.A link to the.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos' proprietary iLution platform, a novel ophthalmic drug-delivery syste.

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.